The pharmaceutical industry is on the cusp of transformative changes over the next decade. Driven by new legislation and technological advancements, companies are rethinking traditional practices. The Biosecure Act, soon to be enacted in the US, and the rise of AI and automation, are key drivers of
The biopharmaceutical industry has witnessed significant advancements in upstream bioprocessing over the years, but downstream bioprocessing (DSP) often lagged, creating bottlenecks that hampered overall efficiency. Recent innovations, however, are transforming the DSP landscape, offering promising
RTI Surgical has recently taken a significant step in enhancing its capabilities in regenerative medicine through the strategic acquisition of Collagen Solutions. This move is set to expand RTI’s portfolio in biomaterials, which further establishes the company as a leader in the biomedical sector.
The Biosecure Act, proposed by the U.S. government last year, aims to safeguard national security by regulating how genetic and biological data are handled, specifically targeting entities linked to adversarial governments like China. With a focus on preventing U.S. federal agencies from engaging
The biopharmaceutical industry is on the cusp of a revolutionary transformation that promises to redefine its future trajectory. While Biopharma 4.0 brought about significant advancements in digitization and smart manufacturing, its successor, Biopharma 5.0, aims to integrate human creativity,
Bioprocessing, with its roots in the early days of microbial fermentation, now stands as a fundamental pillar in the realm of modern biotechnology. This sophisticated field merges biological and engineering principles to harness the power of living organisms in producing a vast array of valuable
